There must be a way out of here: Identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 246-247

  Lowenstein, P R ^a   Yadav, Viveka Nand ^a   Chockley, Peter ^a   Castro, Maria ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DECARBOXYLASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PARVOVIRUS VECTOR;

ASTROCYTE; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN CORTEX; CEREBELLUM; CEREBELLUM DISEASE; CISTERNA MAGNA; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MICROGLIA; MOTOR COORDINATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; NOTE; PHENOTYPE; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTIGEN PRESENTING CELL; CENTRAL NERVOUS SYSTEM; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGEN-PRESENTING CELLS; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; INFLAMMATION;

EID: 84893226252     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.297     Document Type: Note

References (13)

1. Mingozzi, F and High, KA. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122: 23-36.
2. Lowenstein, PR, Mandel, RJ, Xiong, WD, Kroeger, K and Castro, MG (2007). Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther 7: 347-360.
3. Ciesielska, A, Hadaczek, P, Mittermeyer, G, Zhou, S, Wright, JF, Bankiewicz, KS and Forsayeth, J (2013). Cerebral infusion of AAV9 vector encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21: 158-166.
4. Samaranch, L, San Sebastian, W, Kells, AP, Salegio, EA, Heller, G, Bringas, JR et al. (2014). AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 22: 329-337.
5. Fiandaca, MS and Bankiewicz KS. (2010). Gene therapy for Parkinson′s disease: from non-human primates to humans. Curr Opin Mol Ther 12: 519-529.
6. Coune, PG, Schneider, BL and Aebischer, P (2012). Parkinson′s disease: gene therapies. Cold Spring Harb Perspect Med 2: a009431.
7. Kordower, JH and Bjorklund, A (2013). Trophic factor gene therapy for Parkinson′s disease. Mov Disord 28: 96-109.
8. Barcia, C, Jimenez-Dalmaroni, M, Kroeger, KM, Puntel, M, Rapaport, AJ, Larocque, D et al. (2007). One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing antiadenoviral immunity: clinical implications. Mol Ther 15: 2154-2163.
9. Xiong, W, Candolfi, M, Kroeger, KM, Puntel, M, Mondkar, S, Larocque, D et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 16: 343-351.
10. Chenuaud, P et al. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304.
11. Gao, G, Lebherz, C, Weiner, DJ, Grant, R, Calcedo, R, McCullough, B et al. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302.
12. ClinicalTrials.gov. AADC gene therapy for Parkinson′s disease (NCT01973543) .
13. ClinicalTrials.gov. AAV2-GDNF for advanced Parkinson′s disease (NCT01621581) (27 November 2013).